AU Patent

AU2016349279A1 — Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer

Assigned to Genentech Inc · Expires 2018-05-10 · 8y expired

What this patent protects

The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

USPTO Abstract

The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016349279A1
Jurisdiction
AU
Classification
—
Expires
2018-05-10
Drug substance claim
No
Drug product claim
No
Assignee
Genentech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.